Sarcoma botryoides: Difference between revisions

Jump to navigation Jump to search
Line 73: Line 73:
== Natural History, Complications and Prognosis==
== Natural History, Complications and Prognosis==
*The majority of [[patients]] with sarcoma botryoides remain [[asymptomatic]].  
*The majority of [[patients]] with sarcoma botryoides remain [[asymptomatic]].  
*Classic textbook presentation of ‘grape-like’ vaginal tissue loss.<ref name="pmid25519859">{{cite journal| author=van Sambeeck SJ, Mavinkurve-Groothuis AM, Flucke U, Dors N| title=Sarcoma botryoides in an infant. | journal=BMJ Case Rep | year= 2014 | volume= 2014 | issue=  | pages=  | pmid=25519859 | doi=10.1136/bcr-2013-202080 | pmc=4275735 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25519859  }}</ref>
*Early clinical features include [[vaginal discharge]], and vaginal bleeding.<ref name="sadma">Sarcoma Botryoides. Libre Pathology https://librepathology.org/w/index.php?title=Rhabdomyosarcoma&redirect=no#Subtypes_of_embryonal_RMS Accessed on May 11, 2016 </ref>
*If left untreated, patients with sarcoma botryoides may progress to develop direct extension to pelvic soft tissue structures.  
*If left untreated, patients with sarcoma botryoides may progress to develop direct extension to pelvic soft tissue structures.  
*If a patient presents with the classical presentation of a grape-like vaginal tissue, every doctor should be alarmed and commence rapid diagnosis followed by therapy.<ref name="pmid25519859">{{cite journal| author=van Sambeeck SJ, Mavinkurve-Groothuis AM, Flucke U, Dors N| title=Sarcoma botryoides in an infant. | journal=BMJ Case Rep | year= 2014 | volume= 2014 | issue=  | pages=  | pmid=25519859 | doi=10.1136/bcr-2013-202080 | pmc=4275735 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25519859  }}</ref>
*Common complications of sarcoma botryoides, include:
*Common complications of sarcoma botryoides, include:
:*[[Bleeding]]
:*[[Bleeding]]
:*[[Infertility]]  
:*[[Infertility]]  
*Prognosis is generally poor, and the median survival rate of patients with sarcoma botryoides is approximately 10 to 35%.
:*Death
*Favorable prognostic parameters:<ref name="pmid195314572" />
*Favorable prognostic parameters:<ref name="pmid195314572" />
**Disease without deep myometrial invasion
**Disease without deep myometrial invasion
**Single polyp  
**Single polyp  
**Embryonal histologic subtype
**Embryonal histologic subtype
* Poor prognostic factors include:<ref name="pmid11505068">{{cite journal| author=Esnaola NF, Rubin BP, Baldini EH, Vasudevan N, Demetri GD, Fletcher CD et al.| title=Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. | journal=Ann Surg | year= 2001 | volume= 234 | issue= 2 | pages= 215-23 | pmid=11505068 | doi= | pmc=1422009 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11505068  }}</ref>
** Metastatic disease at presentation
** Poor response to chemotherapy


== Diagnosis ==  
== Diagnosis ==  
=== Symptoms ===
=== Symptoms ===
*Sarcoma botryoides may be initially asymptomatic.
*Sarcoma botryoides may be initially asymptomatic.
*Symptoms of sarcoma botryoides may include the following:
*A classic textbook presentation of sarcoma botryoides is a ‘grape-like’ vaginal tissue loss.<ref name="pmid25519859" />
*Symptoms of sarcoma botryoides may include the following:<ref name="sadma" />
:*[[Vaginal bleeding]]
:*[[Vaginal bleeding]]
:*Vaginal discharge
:**Watery
:**Blood-tinged
:**Malodorous
:*[[Irritability]]  
:*[[Irritability]]  
:*Watery, blood-tinged, or malodorous vaginal discharge


=== Physical Examination ===
=== Physical Examination ===
Line 107: Line 113:
== Treatment ==
== Treatment ==
=== Medical Therapy ===
=== Medical Therapy ===
*The classical presentation should alarm every doctor since a rapid diagnosis followed by treatment is necessary to prevent death.<ref name="pmid25519859" />
*The most effective treatment for this tumor has still not been well established and is a subject of on-going investigation.  
*The most effective treatment for this tumor has still not been well established and is a subject of on-going investigation.  
*Due to the lack of data on surgical interventions and histopathological prognostic factors of sarcoma botryoides cases and the variation in management approaches, it is difficult to set a definitive treatment path.<ref name="pmid26357564" />  
*Due to the lack of data on surgical interventions and histopathological prognostic factors of sarcoma botryoides cases and the variation in management approaches, it is difficult to set a definitive treatment path.<ref name="pmid26357564" />  

Revision as of 00:46, 30 April 2019

WikiDoc Resources for Sarcoma botryoides

Articles

Most recent articles on Sarcoma botryoides

Most cited articles on Sarcoma botryoides

Review articles on Sarcoma botryoides

Articles on Sarcoma botryoides in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Sarcoma botryoides

Images of Sarcoma botryoides

Photos of Sarcoma botryoides

Podcasts & MP3s on Sarcoma botryoides

Videos on Sarcoma botryoides

Evidence Based Medicine

Cochrane Collaboration on Sarcoma botryoides

Bandolier on Sarcoma botryoides

TRIP on Sarcoma botryoides

Clinical Trials

Ongoing Trials on Sarcoma botryoides at Clinical Trials.gov

Trial results on Sarcoma botryoides

Clinical Trials on Sarcoma botryoides at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Sarcoma botryoides

NICE Guidance on Sarcoma botryoides

NHS PRODIGY Guidance

FDA on Sarcoma botryoides

CDC on Sarcoma botryoides

Books

Books on Sarcoma botryoides

News

Sarcoma botryoides in the news

Be alerted to news on Sarcoma botryoides

News trends on Sarcoma botryoides

Commentary

Blogs on Sarcoma botryoides

Definitions

Definitions of Sarcoma botryoides

Patient Resources / Community

Patient resources on Sarcoma botryoides

Discussion groups on Sarcoma botryoides

Patient Handouts on Sarcoma botryoides

Directions to Hospitals Treating Sarcoma botryoides

Risk calculators and risk factors for Sarcoma botryoides

Healthcare Provider Resources

Symptoms of Sarcoma botryoides

Causes & Risk Factors for Sarcoma botryoides

Diagnostic studies for Sarcoma botryoides

Treatment of Sarcoma botryoides

Continuing Medical Education (CME)

CME Programs on Sarcoma botryoides

International

Sarcoma botryoides en Espanol

Sarcoma botryoides en Francais

Business

Sarcoma botryoides in the Marketplace

Patents on Sarcoma botryoides

Experimental / Informatics

List of terms related to Sarcoma botryoides

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roukoz A. Karam, M.D.[2] Maria Fernanda Villarreal, M.D. [3]

Synonyms and keywords: Vaginal sarcoma; Embryonal vaginal rhabdomyosarcoma; Botryoid tumor

Overview

Sarcoma botryoides is a rare subtype of embryonal rhabdomyosarcoma. The botryoides subtype of embryonal rhabdomyosarcoma accounts for about 10% of all rhabdomyosarcoma cases and arises under the mucosal surface of body orifices such as the vagina, bladder and cervix. The most common clinical finding is vaginal bleeding. Sarcoma botryoides was first described by Guersant in 1854. Genes involved in the development of sarcoma botryoides include K-ras gene and P53 oncogene. It is more commonly observed among girls aged 3 to 8 years old. If left untreated, patients with sarcoma botryoides may progress to develop direct extension to pelvic soft tissue structures. The mainstay of therapy for sarcoma botryoides is surgery and adjuvant multi-agent chemotherapy.

Historical Perspective

  • Sarcoma botryoides was first described by Guersant in 1854.[1]
    • The patient, a 13-month-old infant, had a polyp of the vagina that grew quite rapidly and resulted in death 2 months after it was first noted.
    • Granicher is said to have been the first to observe sarcoma botryoides at birth.
  • Pfannenstiel in 1892 actually was the first to call attention to the "grapelike" appearance of the tumor.[2]
    • The term “sarcoma botryoides” based on the tumor's gross appearance, has persisted in literature.

Classification

  • There is no established system for the staging of sarcoma botryoides.
  • Sarcoma botryoides is a rare subtype of embryonal rhabdomyosarcoma.

Pathophysiology

  • The pathogenesis of sarcoma botryoides is not fully understood.
  • Genes involved in the development of sarcoma botryoides, include:
  • On gross pathology, characteristic findings of sarcoma botryoides, include:[3]
  • Grape-like morphology
  • Fleshy nodular polypoid projections
  • On microscopic histopathological analysis, characteristic findings of sarcoma botryoides include:[3][4]
  • Rhabdomyoblasts
    • May include cross-striations
  • Myxoid stroma
  • Cambium layer
  • Spindle-shaped tumor cells
  • Randomly arranged small cells
  • Tadpole-like morphology
  • Desmin and MyoD1 postivie

Causes

  • There are no established causes for sarcoma botryoides.[3]

Differentiating Sarcoma Botryoides from Other Diseases

Epidemiology and Demographics

Incidence

  • Sarcoma botryoides is very rare.
  • The prevalence of sarcoma botryoides remains unknown.[3]

Age

  • The incidence of sarcoma botryoides decreases with age; the median age at diagnosis is 3 years.[6]
  • Sarcoma botryoides is more commonly observed among patients aged 3 to 8 years old.
  • Sarcoma botryoides is more commonly observed among young children.

Gender

  • Sarcoma botryoides affects females more frequently than males.

Race

  • There is no racial predilection to sarcoma botryoides.

Risk Factors

  • There are no risk factors associated with the development of sarcoma botryoides.[7]

Natural History, Complications and Prognosis

  • The majority of patients with sarcoma botryoides remain asymptomatic.
  • If left untreated, patients with sarcoma botryoides may progress to develop direct extension to pelvic soft tissue structures.
  • If a patient presents with the classical presentation of a grape-like vaginal tissue, every doctor should be alarmed and commence rapid diagnosis followed by therapy.[8]
  • Common complications of sarcoma botryoides, include:
  • Favorable prognostic parameters:[9]
    • Disease without deep myometrial invasion
    • Single polyp
    • Embryonal histologic subtype
  • Poor prognostic factors include:[10]
    • Metastatic disease at presentation
    • Poor response to chemotherapy

Diagnosis

Symptoms

  • Sarcoma botryoides may be initially asymptomatic.
  • A classic textbook presentation of sarcoma botryoides is a ‘grape-like’ vaginal tissue loss.[8]
  • Symptoms of sarcoma botryoides may include the following:[3]

Physical Examination

  • Physical examination showed no abnormalities, but vaginal examination showed abnormal vaginal tissue protruding through the vagina introitus.[8]

Laboratory Findings

  • There are no specific laboratory findings associated with sarcoma botryoides.

Imaging Findings

  • There are no specific imaging findings associated with sarcoma botryoides.[3]
  • MRI of the abdominal region shows a solid lesion arising from the vagina and is:[8]
    • non-homogeneous
    • Polycyclic
    • Grape-like

Treatment

Medical Therapy

  • The most effective treatment for this tumor has still not been well established and is a subject of on-going investigation.
  • Due to the lack of data on surgical interventions and histopathological prognostic factors of sarcoma botryoides cases and the variation in management approaches, it is difficult to set a definitive treatment path.[11]
  • From the available literature, it appears that limited surgery with adjuvant multi-agent chemotherapy is feasible in the treatment of sarcoma bortyoides.[11]
  • The mainstay of therapy for sarcoma botryoides, include:

Surgery

  • Surgery is the mainstay of therapy for sarcoma botryoides.
  • Patients with favorable prognostic parameters can effectively be treated by surgery.[9]
  • Patients with unfavorable prognostic parameters seem to benefit from a multimodality approach including surgery + adjuvant chemotherapy and radiotherapy.[9]

Prevention

  • There are no primary preventive measures available for sarcoma botryoides.

References

  1. Rao, P. L. N. G.; Aithala, G.; Warrier, P. K. R. (1983). "Sarcoma botryoides of the vagina". The Indian Journal of Pediatrics. 50 (4): 445–448. doi:10.1007/BF02753388. ISSN 0019-5456.
  2. Hellriegel, W. (1985). "Primäre Sarkome der Weichteile". 19 / 6: 25–109. doi:10.1007/978-3-642-82387-9_2. ISSN 0085-1396.
  3. 3.0 3.1 3.2 3.3 3.4 3.5 Sarcoma Botryoides. Libre Pathology https://librepathology.org/w/index.php?title=Rhabdomyosarcoma&redirect=no#Subtypes_of_embryonal_RMS Accessed on May 11, 2016
  4. Palazzo JP, Gibas Z, Dunton CJ, Talerman A (1993). "Cytogenetic study of botryoid rhabdomyosarcoma of the uterine cervix". Virchows Arch A Pathol Anat Histopathol. 422 (1): 87–91. PMID 8438559.
  5. Zanetta G, Rota SM, Lissoni A, Chiari S, Bratina G, Mangioni C (1999). "Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females". Br J Cancer. 80 (3–4): 403–6. doi:10.1038/sj.bjc.6690370. PMC 2362332. PMID 10408845.
  6. Hilgers RD (1975). "Pelvic exenteration for vaginal embryonal rhabdomyosarcoma: a review". Obstet Gynecol. 45 (2): 175–80. PMID 1090863.
  7. Comprehensive treatment for sarcoma botryoides of uterine cervix. Chinese Journal of Cancer Research June 1991, Volume 3, Issue 2, pp 68-70 <nowiki>
  8. 8.0 8.1 8.2 8.3 van Sambeeck SJ, Mavinkurve-Groothuis AM, Flucke U, Dors N (2014). "Sarcoma botryoides in an infant". BMJ Case Rep. 2014. doi:10.1136/bcr-2013-202080. PMC 4275735. PMID 25519859.
  9. 9.0 9.1 9.2 Koukourakis GV, Kouloulias V, Zacharias G, Maravelis G, Papadimitriou C, Platoni K; et al. (2009). "Embryonal rhabdomyosarcoma of the uterine cervix". Clin Transl Oncol. 11 (6): 399–402. PMID 19531457.
  10. Esnaola NF, Rubin BP, Baldini EH, Vasudevan N, Demetri GD, Fletcher CD; et al. (2001). "Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma". Ann Surg. 234 (2): 215–23. PMC 1422009. PMID 11505068.
  11. 11.0 11.1 Neha B, Manjunath AP, Girija S, Pratap K (2015). "Botryoid Rhabdomyosarcoma of the Cervix: Case report with review of the literature". Sultan Qaboos Univ Med J. 15 (3): e433–7. doi:10.18295/squmj.2015.15.03.022. PMC 4554283. PMID 26357564.